Roche said it has received European approval for its Actemra medication in giant cell arteritis (GCA):
“As the first effective non-steroid therapy for GCA, Actemra/RoActemra has the potential to fundamentally change how this condition is treated,” Sandra Horning, Roche’s chief medical officer and global head of product development, said in a statement.
Roche has also received European Union approval of Gazyvaro for people with previously untreated advanced follicular lymphoma.
Source: Reuters
